Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2)
Pleura and Peritoneum · 2019
DOI: 10.1515/pp-2016-0017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pleura and Peritoneum, 2019. Verfasst von Vladimir Khomyakov und 6 weiteren Autor:innen. Beteiligte Einrichtung: Moscow Research Oncological Institute n.a. P.A. Herzen, Thoracoabdominal, 2-nd Botkinsky proesd, 3, Moscow 125284, Russian Federation. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Peritoneal metastasis (PM) develop in more than 50 % of gastric cancer (GC) patients. Median survival without treatment is not more than 3–7 months, and 8–12 months after modern combination chemotherapy. Innovative therapeutic approaches are urgently needed.
Methods
Phase-2, open label prospective clinical trial assessing safety and efficacy of bidirectional chemotherapy for treating peritoneal metastasis of gastric cancer (PMGC). Treatment protocol included initial staging laparoscopy or laparotomy, 3–4 courses of systemic chemotherapy (XELOX) followed by Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) procedures every 6 weeks until progression of disease or death. Primary endpoints were overall survival and histological peritoneal regression grading score after rebiopsy.
Results
31 patients were included (9 men, 22 women, mean age 52 years), 24 with synchronous PM at diagnosis, 7 with metachronous PM after previous chemotherapy. Mean PCI was 13.8 (min-max 6–34). XELOX was administered in all patients and combined with 56 PIPAC procedures. Complete and partial pathological response was found in 60 % of the 15 patients eligible for tumor response assessment (4 and 5 patients, respectively). Median survival was 13 months.
Conclusions
Bidirectional chemotherapy combining XELOX with PIPAC with cisplatin and doxororubicin is well tolerated, can induce objective tumor regression and is associated with a promising survival in PMGC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Moscow Research Oncological Institute n.a. P.A. Herzen, Thoracoabdominal, 2-nd Botkinsky proesd, 3, Moscow 125284, Russian Federation.
- Moscow Research Oncological Institute n.a. P.A. Herzen, Thoracoabdominal, Moscow, Russian Federation.
- Moscow Research Oncological Institute n.a. P.A. Herzen, Chemotherapy.
- Moscow Research Oncological Institute n.a. P.A. Herzen, Pathology.
- Moscow Research Oncological Institute n.a. P.A. Herzen, Director General.
Zitieren
APA
Khomyakov, V., Ryabov, A., Ivanov, A., Bolotina, L., Utkina, A., Volchenko, N., & Kaprin, A. (2019). Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2). Pleura and Peritoneum. https://doi.org/10.1515/pp-2016-0017
Vancouver
Khomyakov V, Ryabov A, Ivanov A, Bolotina L, Utkina A, Volchenko N, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2). Pleura and Peritoneum. 2019. doi:10.1515/pp-2016-0017
BibTeX
@article{Khomyakov2019,
author = {Khomyakov, Vladimir and Ryabov, Andrey and Ivanov, Andrey and Bolotina, Larisa and Utkina, Anna and Volchenko, Nadezhda and Kaprin, Andrey},
title = {Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2)},
journal = {Pleura and Peritoneum},
year = {2019},
doi = {10.1515/pp-2016-0017}
}
EUVIMED